A Comparison of Retrospective Database Analysis with Chart Review in Patients Receiving Somatostatin Analog (SSA) in Neuroendocrine Tumors (NETs)

#2160

Introduction: SSAs are recommended for the treatment of locoregional/metastatic NET.

Aim(s): The objective of this study was to understand SSA dose/frequency patterns using claims data vs patient (pt) chart data in the US after the approval of lanreotide depot (LAN) in the US for gastrointestinal (GI) and pancreatic NET.

Materials and methods: This analysis examined a subgroup of pts from an existing patient-level US claims data set (1/2015-12/2016) then compared to additional physician-reported clinical data. Physicians of pts (108 LAN; 440 octreotide LAR (OCT)) in the claims analysis were asked to complete chart reviews. Pts identified with metastatic NET (lung, GI or pancreatic) were indexed at the earliest initiation of treatment with an SSA. Treatment patterns and dosing/frequency of SSAs were described from NET diagnosis through treatment change.

Conference: 15th Annual ENETSConcerence (2018)

Presenting Author:

Authors: Klink A, Feinberg B, Yu H, Ray D, Pulgar S,

Keywords: neuroendocrine tumors, somatostatin analogues, lanreotide, octreotide, carcinoid syndrome,